Effects of topical treatment with fenretinide (4-HPR) and plasma vitamin A levels in patients with actinic keratoses

Daniele Moglia, Franca Formelli, Gianandrea Baliva, Aldo Bono, Mariapia Accetturi, Maurizio Nava, Giuseppe De Palo

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Eighteen patients with facial actinic keratoses were treated with the retinoid fenretinide (4-HPR), applied topically twice-daily for 3 months. After 3 months of treatment, complete regression was observed in 56% and partial regression in 44% of cases. Eight patients relapsed within 3 months after drug discontinuation. Six months later, only two patients (11%) showed a treatment response (complete regression). Blood samples showed that 4-HPR was not absorbed and no local or distant adverse effects were observed. Baseline plasma retinol levels were lower than in healthy subjects, thus suggesting that reduced retinol levels might be involved in this pathology. These encouraging preliminary results suggest the need for further studies to evaluate the best dosage schedules and duration of 4-HPR topical application in actinic keratoses.

Original languageEnglish
Pages (from-to)87-91
Number of pages5
JournalCancer Letters
Volume110
Issue number1-2
DOIs
Publication statusPublished - Dec 20 1996

Fingerprint

Fenretinide
Actinic Keratosis
Vitamin A
Retinoids
Therapeutics
Appointments and Schedules
Healthy Volunteers
Pathology
Pharmaceutical Preparations

Keywords

  • Cancer prevention
  • Fenretinide
  • Topical application

ASJC Scopus subject areas

  • Cancer Research
  • Molecular Biology
  • Oncology

Cite this

Effects of topical treatment with fenretinide (4-HPR) and plasma vitamin A levels in patients with actinic keratoses. / Moglia, Daniele; Formelli, Franca; Baliva, Gianandrea; Bono, Aldo; Accetturi, Mariapia; Nava, Maurizio; De Palo, Giuseppe.

In: Cancer Letters, Vol. 110, No. 1-2, 20.12.1996, p. 87-91.

Research output: Contribution to journalArticle

Moglia, Daniele ; Formelli, Franca ; Baliva, Gianandrea ; Bono, Aldo ; Accetturi, Mariapia ; Nava, Maurizio ; De Palo, Giuseppe. / Effects of topical treatment with fenretinide (4-HPR) and plasma vitamin A levels in patients with actinic keratoses. In: Cancer Letters. 1996 ; Vol. 110, No. 1-2. pp. 87-91.
@article{15e2626cb0a64009a8fbdf6ad73507e1,
title = "Effects of topical treatment with fenretinide (4-HPR) and plasma vitamin A levels in patients with actinic keratoses",
abstract = "Eighteen patients with facial actinic keratoses were treated with the retinoid fenretinide (4-HPR), applied topically twice-daily for 3 months. After 3 months of treatment, complete regression was observed in 56{\%} and partial regression in 44{\%} of cases. Eight patients relapsed within 3 months after drug discontinuation. Six months later, only two patients (11{\%}) showed a treatment response (complete regression). Blood samples showed that 4-HPR was not absorbed and no local or distant adverse effects were observed. Baseline plasma retinol levels were lower than in healthy subjects, thus suggesting that reduced retinol levels might be involved in this pathology. These encouraging preliminary results suggest the need for further studies to evaluate the best dosage schedules and duration of 4-HPR topical application in actinic keratoses.",
keywords = "Cancer prevention, Fenretinide, Topical application",
author = "Daniele Moglia and Franca Formelli and Gianandrea Baliva and Aldo Bono and Mariapia Accetturi and Maurizio Nava and {De Palo}, Giuseppe",
year = "1996",
month = "12",
day = "20",
doi = "10.1016/S0304-3835(96)04475-8",
language = "English",
volume = "110",
pages = "87--91",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - Effects of topical treatment with fenretinide (4-HPR) and plasma vitamin A levels in patients with actinic keratoses

AU - Moglia, Daniele

AU - Formelli, Franca

AU - Baliva, Gianandrea

AU - Bono, Aldo

AU - Accetturi, Mariapia

AU - Nava, Maurizio

AU - De Palo, Giuseppe

PY - 1996/12/20

Y1 - 1996/12/20

N2 - Eighteen patients with facial actinic keratoses were treated with the retinoid fenretinide (4-HPR), applied topically twice-daily for 3 months. After 3 months of treatment, complete regression was observed in 56% and partial regression in 44% of cases. Eight patients relapsed within 3 months after drug discontinuation. Six months later, only two patients (11%) showed a treatment response (complete regression). Blood samples showed that 4-HPR was not absorbed and no local or distant adverse effects were observed. Baseline plasma retinol levels were lower than in healthy subjects, thus suggesting that reduced retinol levels might be involved in this pathology. These encouraging preliminary results suggest the need for further studies to evaluate the best dosage schedules and duration of 4-HPR topical application in actinic keratoses.

AB - Eighteen patients with facial actinic keratoses were treated with the retinoid fenretinide (4-HPR), applied topically twice-daily for 3 months. After 3 months of treatment, complete regression was observed in 56% and partial regression in 44% of cases. Eight patients relapsed within 3 months after drug discontinuation. Six months later, only two patients (11%) showed a treatment response (complete regression). Blood samples showed that 4-HPR was not absorbed and no local or distant adverse effects were observed. Baseline plasma retinol levels were lower than in healthy subjects, thus suggesting that reduced retinol levels might be involved in this pathology. These encouraging preliminary results suggest the need for further studies to evaluate the best dosage schedules and duration of 4-HPR topical application in actinic keratoses.

KW - Cancer prevention

KW - Fenretinide

KW - Topical application

UR - http://www.scopus.com/inward/record.url?scp=0030596183&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030596183&partnerID=8YFLogxK

U2 - 10.1016/S0304-3835(96)04475-8

DO - 10.1016/S0304-3835(96)04475-8

M3 - Article

VL - 110

SP - 87

EP - 91

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

IS - 1-2

ER -